Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 12/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619538 | 1.00 | KCNA3 (0.46) | KCNA3MEN1OPRM1HRH1 | |
| SCHEMBL14125383 | 1.00 | KCNA3 (0.46) | KCNA3MEN1OPRM1HRH1 | |
| SCHEMBL11226666 | 0.88 | KCNA3 (0.40) | KCNA3MEN1OPRM1 | |
| SCHEMBL11832164 | 0.87 | MEN1 (0.42) | KCNA3MEN1 | |
| SCHEMBL11732329 | 0.85 | KCNA3 (0.43) | KCNA3MEN1 | |
| SCHEMBL956109 | 0.84 | KCNA3 (0.49) | KCNA3HRH1 | |
| SCHEMBL956111 | 0.84 | KCNA3 (0.49) | KCNA3HRH1 | |
| Hydrochloric Acid SCHEMBL954583 | 0.83 | KCNA3 (0.48) | KCNA3HRH1 | |
| Hydrochloric Acid SCHEMBL954585 | 0.83 | KCNA3 (0.48) | KCNA3HRH1 | |
| SCHEMBL10867644 | 0.83 | KCNA3 (0.44) | KCNA3MEN1OPRM1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | KCNA3 1388/4885MEN1 2021/4885OPRM1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.